touchNEUROLOGY met up with Prof. Giuseppe Lauria Pinter (University of Milan, Milan, Italy) to discuss the efficacy and outcome measures of a phase 2 study investigating guanabenz for the treatment of amyotrophic lateral sclerosis.
The abstract entitled: ‘The unfolded protein response in Amyotrophic lateral sclerosis: Results of a Phase 2 Trial’ was presented at the XXV Biennial World Congress of Neurology (WCN) 2021, 3 Oct 2021 – 7 Oct 2021.
Questions:
- What is known about endoplasmic reticulum stress in the pathogenesis of amyotrophic lateral sclerosis (ALS)? (0:19)
- What is the mechanism of action of guanabenz? (3:46)
- What were the aims and design of your Phase II trial? (5:53)
- What were the efficacy and outcome measures and how well were they achieved? (6:42)
- What were the conclusions of the investigators and what future studies are planned? (10:53)
Disclosures: Giuseppe Lauria Pinter has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of WCN, Virtual 2021
